Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

52
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
52
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

56
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
56
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

66
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
66
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

41
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
41
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

36
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
36
Renal Corpuscle01:20

Renal Corpuscle

3.0K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metal-polyphenol cross-linked titanium carbide membranes with stable interlayer spacing for efficient wastewater treatment.

Journal of colloid and interface science·2022
Same author

A new surgical approach for a child with acute torsion of the wandering spleen: A case report.

Asian journal of surgery·2022
Same author

Blood protein biomarkers in lung cancer.

Cancer letters·2022
Same author

Metformin attenuates osteoarthritis by targeting chondrocytes, synovial macrophages and adipocytes.

Rheumatology (Oxford, England)·2022
Same author

PLK1 promotes cholesterol efflux and alleviates atherosclerosis by up-regulating ABCA1 and ABCG1 expression via the AMPK/PPARγ/LXRα pathway.

Biochimica et biophysica acta. Molecular and cell biology of lipids·2022
Same author

CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cells.

BMC cancer·2022

Related Experiment Video

Updated: Aug 8, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.6K

VX-765 ameliorates CKD VSMC calcification by regulating STAT3 activation.

Yingjie Duan1, Zhong Peng2, Shuzhu Zhong1

  • 1The First Affiliated Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, China.

European Journal of Pharmacology
|March 1, 2023
PubMed
Summary

The caspase-1 inhibitor VX-765 reduces vascular calcification in chronic kidney disease (CKD) rats by inhibiting pyroptosis. This study suggests VX-765 as a potential treatment for vascular calcification in CKD patients.

Keywords:
CalcificationCaspase-1PyroptosisVascular smooth muscle cells

More Related Videos

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models
09:01

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models

Published on: January 27, 2023

1.7K
Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification
08:55

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification

Published on: November 20, 2017

9.8K

Related Experiment Videos

Last Updated: Aug 8, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
08:43

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

19.6K
Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models
09:01

Analysis of Extracellular Vesicle-Mediated Vascular Calcification Using In Vitro and In Vivo Models

Published on: January 27, 2023

1.7K
Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification
08:55

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification

Published on: November 20, 2017

9.8K

Area of Science:

  • Cardiovascular Research
  • Nephrology
  • Molecular Biology

Background:

  • Vascular calcification is a complication of chronic kidney disease (CKD).
  • Caspase-1 inhibitor VX-765 shows promise in atherosclerosis, but its effect on CKD-related vascular calcification is unknown.
  • This study investigates VX-765's impact on hyperphosphatemia-induced vascular calcification in CKD.

Purpose of the Study:

  • To evaluate the effect of VX-765 on vascular smooth muscle cell (VSMC) calcification in hyperphosphatemia.
  • To assess VX-765's efficacy in preventing vascular calcification in a rat model of CKD.
  • To elucidate the molecular mechanisms underlying VX-765's action.

Main Methods:

  • VSMC calcification assessed using Alizarin Red S staining.
  • Aortic calcification in CKD rats evaluated via micro-CT scanning.
  • Expression of NLRP3, caspase-1, and GSDMD measured by qPCR, western blotting, and immunohistochemistry.

Main Results:

  • NLRP3, caspase-1, GSDMD, IL-1β, and IL-18 were upregulated in hyperphosphatemia-induced VSMCs.
  • VX-765 inhibited VSMC calcification and pyroptosis-related molecules in vitro.
  • VX-765 treatment reduced vascular calcification in CKD rats and inhibited STAT3 activation.

Conclusions:

  • VX-765 effectively inhibits hyperphosphatemia-induced VSMC calcification and ameliorates vascular calcification in CKD rats.
  • The findings suggest VX-765 as a potential therapeutic strategy for CKD-associated vascular calcification.
  • Caspase-1 and pyroptosis are key players in CKD vascular calcification.